EGFR and non-small cell lung carcinoma: Molecularly targeted drugs such as erlotinib and gefitinib have thus greatly improved the clinical outcome of advanced NSCLC patients harboring sensitive epidermal growth factor receptor (EGFR) gene mutations [3].